US Government Drug Pricing ‘Negotiation:’ Where We Go From Here
Executive Summary
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
You may also be interested in...
Do R&D Spending And Approvals Really Measure Innovation?
A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.
Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill
Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry.
At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.